Xalud Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for neuroinflammatory diseases and inflammatory joint disorders such as osteoarthritis and rheumatoid arthritis. The company specializes in non-opioid gene therapy solutions aimed at alleviating chronic pain by rebalancing pain signals. Xalud's core technology, developed by Dr. Linda Watkins at the University of Colorado, Boulder, targets glial cells to modulate pain pathways effectively. The company primarily serves patients suffering from chronic pain conditions and inflammatory diseases, offering a promising alternative to traditional opioid treatments. Xalud operates in the biopharmaceutical market, leveraging cutting-edge gene therapy techniques to create long-lasting pain relief solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary therapies. Revenue is generated through partnerships, investments, and future sales of approved treatments.

Keywords: gene therapy, chronic pain, neuroinflammatory, osteoarthritis, rheumatoid arthritis, non-opioid, glial cells, biotechnology, pain management, biopharmaceutical.